Previous 10 |
home / stock / crdl:cc / crdl:cc news
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation . Here we discuss the FDA’s Orphan Drug Designation pro...
Third IND authorization for CardiolRx™ in cardiovascular disease Study to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indications Oakville, Ont...
Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked . People with type 2 diabetes are two to four times more likely to develop heart failure than someone without diabetes. Heart failure i...
Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19 Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical t...
Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiova...
Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiova...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL:CC Stock Symbol:
TSXC Market:
Cardiol Therapeutics Inc. Website:
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain CardiolRx™ also shown to reduce inflammation in patients with elevated CRP 89% of patients have continued into the extension phase of the study Toronto, Ontario--(Newsfile...